Wagner Paul A. 4
4 · Forte Biosciences, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Forte (FBRX) CEO Paul Wagner Receives 500,000-Share Award
What Happened Paul A. Wagner, CEO, Secretary and Chair of the Board of Forte Biosciences (FBRX), was granted 500,000 derivative shares on June 16, 2026. The reported acquisition price is $0.00 (a grant/award rather than an open-market purchase). This is an equity award subject to vesting rather than an immediate cash transaction or sale.
Key Details
- Transaction date: June 16, 2026; Form 4 filed June 17, 2026 (timely).
- Security: 500,000 derivative shares granted; acquisition price reported as $0.00.
- Vesting: 1/48th of the award vests monthly beginning June 16, 2026; fully vested after four years (June 16, 2030), contingent on continuing service.
- Shares owned after transaction: Not specified in the filing.
- Filing type/remark: Reported as an Award/Grant (code A); Wagner listed as CEO, Secretary and Chair.
Context This filing reflects an equity compensation award that vests over time (commonly RSUs or similar), not an open-market purchase or sale. Such awards are routine for executives and are contingent on continued service; they do not by themselves indicate immediate buying or selling of stock.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-16+500,000→ 500,000 totalExercise: $17.15Exp: 2036-06-16→ Common Stock (500,000 underlying)
Footnotes (1)
- [F1]Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 16, 2026.